Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was reached in Q1 2026; as a result, the analyses of progression-free survival (PFS) and OS are expected

#CMPX Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/CMPX/compass-therap...

Compass Therapeutics Provides Corporate Update Compass Therapeutics (NASDAQ: CMPX) provided a corporate update on January 6, 2026, reporting pipeline progress, leadership hires, upcoming data readouts, and a cash position. Key items include PFS and OS analyses for tovecimig on track for late Q1 2026, a planned Phase 2 DLL4+ basket study following COMPANION-002 analysis, and a 5% ORR (2/40) for tovecimig monotherapy in heavily pretreated colorectal cancer (all had prior bevacizumab).For CTX-8371, cohort expansions in TNBC and NSCLC (n=28 each) are open with dose levels 3.0 and 10.0 mg/kg; a third confirmed response in Hodgkin lymphoma was reported. CTX-10726 Phase 1 is expected to start in Q1 2026. Estimated cash and marketable securities were $209 million as of December 31, 2025, providing runway into 2028.

#CMPX Compass Therapeutics Provides Corporate Update

www.stocktitan.net/news/CMPX/compass-therap...

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of overall survival (OS) and progression-free survival (PFS) are expected in late Q1

#CMPX Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/CMPX/compass-therap...

Cancer Drug Developer Compass Therapeutics Secures $120M to Advance Commercial Plans Oncology biotech prices 40M shares at $3.00, including pre-funded warrants. Funds target commercial readiness and clinical development pipeline. See investment details.

#CMPX Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

www.stocktitan.net/news/CMPX/compass-therap...

Compass Therapeutics Plans Stock Offering to Fund Cancer Drug Development Oncology-focused Compass Therapeutics announces public offering of common stock and pre-funded warrants. Proceeds to support commercial prep and cancer drug development. Learn more.

#CMPX Compass Therapeutics Announces Proposed Public Offering

www.stocktitan.net/news/CMPX/compass-therap...

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update Compass Therapeutics (NASDAQ:CMPX) reported Q2 2025 financial results and provided updates on its oncology pipeline. The company reported a net loss of $19.9 million ($0.14 per share), compared to $13.1 million in Q2 2024. Key highlights include promising survival data for tovecimig in biliary tract cancer, with secondary endpoint analysis now expected in Q1 2026.In the CTX-8371 Phase 1 trial, two significant partial responses were observed in post-checkpoint inhibitor settings, including 100% tumor reduction in a lung cancer patient and >90% reduction in a breast cancer patient. The company's new drug CTX-10726 showed superior results compared to ivonescimab in preclinical studies.Compass ended Q2 with $101 million in cash, providing runway into 2027. R&D expenses increased 47% year-over-year to $16.4 million, primarily due to manufacturing costs for tovecimig and CTX-10726.

#CMPX Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

www.stocktitan.net/news/CMPX/compass-therap...

Small-cap stocks overbought with declining relative strength, Wed Jun 11th - #NEGG #LIMN #KYTX #FTEK #EYEN #CMPX #BIRD #AKBA #YEXT #SANA #THRD #ULBI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update Compass Therapeutics (NASDAQ: CMPX) reported significant progress in Q1 2025, highlighted by tovecimig meeting its primary endpoint in the Phase 2/3 COMPANION-002 study for biliary tract cancer (BTC). The drug achieved a 17.1% overall response rate compared to 5.3% for paclitaxel alone. The company also advanced other pipeline candidates, including CTX-10726 (PD-1 x VEGF-A bispecific antibody) and CTX-8371.Financial results showed a net loss of $16.6 million ($0.12 per share) compared to $10.8 million in Q1 2024. R&D expenses increased 37% to $13.1 million, while G&A expenses rose 51% to $4.9 million. The company maintains a strong financial position with $113 million in cash, providing runway into 2027.

#CMPX Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

www.stocktitan.net/news/CMPX/compass-therap...

Breakthrough: MD Anderson Launches First-Line Trial for Tovecimig in Biliary Cancer Following Phase 2/3 Success New trial explores tovecimig's potential in first-line biliary cancer treatment at MD Anderson. Recent Phase 2/3 success accelerates development. See full protocol details.

#CMPX Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

www.stocktitan.net/news/CMPX/compass-therap...

Breakthrough Cancer Treatment: New Drug Shows 3x Better Results in Rare Cancer Trial Phase 2/3 trial reveals Tovecimig combo therapy achieves 17.1% response rate vs 5.3% for standard care in biliary tract cancer. Major advance for 23,000 US patients.

#CMPX Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

www.stocktitan.net/news/CMPX/tovecimig-ctx-...

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update Compass Therapeutics (NASDAQ: CMPX) reported its 2024 financial results and provided key pipeline updates. The company's lead candidate tovecimig is on track for Phase 2/3 top-line data readout in biliary tract cancer by Q1 2025. The company ended 2024 with $127 million in cash, providing runway into Q1 2027.Financial highlights include a net loss of $49.4 million ($0.36 per share) compared to $42.5 million in 2023. R&D expenses increased 11% to $42.3 million, while G&A expenses rose 24% to $15.1 million.Pipeline progress includes:Advancement of CTX-10726 (PD-1 x VEGF-A bispecific antibody) towards IND filing by end-2025Full enrollment of third dosing cohort for CTX-8371 Phase 1 studyPlanned initiation of two Phase 2 trials in mid-2025 for tovecimig and CTX-4715% ORR achieved for tovecimig in colorectal cancer patients

#CMPX Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/CMPX/compass-therap...

Just In: ( NASDAQ: #CMPX ) Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate

Compass Therapeutics Advances Cancer Pipeline with Strong $127M Cash Position Through 2027 Compass Therapeutics progresses tovecimig Phase 2/3 trial, expands pipeline with CTX-10726, and maintains robust financial position supporting multiple oncology programs through Q1 2027.

#CMPX Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate

www.stocktitan.net/news/CMPX/compass-therap...

NEWS: ( NASDAQ: #CMPX ) Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

#StockMarket #News

News; ( NASDAQ: #CMPX ) Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update

#StockMarket #News